Last updated: October 15, 2026
Vaprisol in 5% Dextrose is the ready-to-use intravenous presentation of conivaptan hydrochloride, a vasopressin V1a/V2 receptor antagonist for hospitalized adults with euvolemic or hypervolemic hyponatremia. The product has a narrow hospital market, limited differentiation from potential generic conivaptan injection, and no publicly reported standalone revenue stream. Its commercial value is driven more by formulary access, supply reliability, and the cost of hospital substitution than by patent exclusivity.
What is Vaprisol in 5% Dextrose?
Vaprisol is supplied as conivaptan hydrochloride injection in a 100 mL container containing 20 mg of conivaptan hydrochloride in 5% dextrose. The concentration is 0.2 mg/mL. The product is administered intravenously in hospitals for short-term treatment of euvolemic or hypervolemic hyponatremia in adults. Treatment is limited to a maximum of four days under the U.S. prescribing information. [1]
| Product characteristic |
Detail |
| Brand |
Vaprisol |
| Active ingredient |
Conivaptan hydrochloride |
| Dosage form |
Intravenous injection |
| Presentation |
20 mg/100 mL in 5% dextrose |
| Therapeutic class |
Vasopressin receptor antagonist |
| Primary use |
Hospital treatment of euvolemic or hypervolemic hyponatremia |
| U.S. approval |
December 1, 2005 |
| Administration |
Loading dose followed by continuous infusion |
| Commercial channel |
Institutional and hospital pharmacy |
| Biologic status |
Small molecule; no biosimilar pathway |
The premixed dextrose container reduces bedside compounding compared with a concentrated vial presentation. That operational benefit can support hospital purchasing, but it does not create the regulatory exclusivity associated with a new active ingredient.
What is the FDA regulatory status of Vaprisol?
Vaprisol received FDA approval through a new drug application for intravenous conivaptan hydrochloride. The FDA-approved indication covers hospitalized adults with euvolemic or hypervolemic hyponatremia, including cases associated with heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone secretion. [1][2]
The product is a small-molecule drug rather than a biologic. A competing manufacturer would generally pursue an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act, rather than a biosimilar application under section 351(k) of the Public Health Service Act.
The main regulatory constraints are clinical and operational:
- Intravenous administration limits use to institutional settings.
- The product requires monitoring of serum sodium and fluid status.
- Conivaptan has clinically significant CYP3A interactions.
- Rapid correction of serum sodium creates a risk of osmotic demyelination.
- The product is intended for short-term use rather than chronic outpatient therapy. [1]
These factors reduce the addressable market compared with oral hyponatremia products.
When did Vaprisol lose exclusivity?
Vaprisol’s meaningful U.S. regulatory exclusivity ended years ago. The product was approved in 2005, and any five-year new chemical entity exclusivity would have expired by December 2010. No current regulatory exclusivity is a material barrier to an ANDA applicant.
The FDA Orange Book entry reviewed for conivaptan hydrochloride injection does not identify an active patent listing that would provide a current Orange Book barrier to generic approval. [3] The commercial analysis therefore turns on generic development economics, manufacturing capability, and market size rather than on a remaining patent term.
| Exclusivity category |
Status |
| New chemical entity exclusivity |
Expired |
| Orphan-drug exclusivity |
Not identified as a current commercial barrier |
| Pediatric exclusivity |
No current barrier identified |
| Listed Orange Book patent protection |
No active blocking listing identified in the reviewed entry |
| Generic approval pathway |
505(j) ANDA |
| Biosimilar pathway |
Not applicable |
What patents protect Vaprisol in 5% Dextrose?
The current patent position appears weak for the marketed product. No active Orange Book patent listing was identified for the conivaptan hydrochloride injection presentation reviewed. [3]
The relevant intellectual-property categories are:
Active-ingredient patents
The active ingredient is conivaptan hydrochloride. Any original compound or composition-of-matter protection has expired or is no longer an effective commercial barrier in the United States.
Formulation patents
The 5% dextrose presentation may involve formulation know-how concerning concentration, pH, stability, container compatibility, and particulate control. No current Orange Book-listed formulation patent was identified for the marketed presentation.
A generic applicant could still face technical development work involving:
- Stability in a premixed dextrose solution.
- Compatibility with plastic container materials.
- Extractables and leachables.
- Container-closure integrity.
- Sterility assurance.
- Infusion-line compatibility.
- Control of degradation products and particulates.
These requirements can increase development cost without creating enforceable exclusivity.
Method-of-use patents
The approved use is treatment of hyponatremia. No current Orange Book-listed method-of-use patent was identified as blocking the approved indication. A generic applicant could seek a section viii carve-out for any separately patented indication, but the commercial importance of that mechanism appears limited for this product.
Are there Paragraph IV challenges to Vaprisol?
No publicly reported Paragraph IV challenge was identified as a material driver of Vaprisol’s current market position. The absence of a prominent Paragraph IV dispute is consistent with the product’s small market, lack of current Orange Book patent protection, and limited expected return on generic investment.
For an ANDA applicant, the likely approval strategy would be:
- Submit an ANDA for conivaptan hydrochloride injection.
- Demonstrate pharmaceutical equivalence and bioequivalence or an FDA-accepted alternative basis for injectable products.
- Address sterility, stability, container closure, and manufacturing controls.
- Certify against any listed patents, if applicable.
- Launch after approval without waiting for a patent term if no blocking patent remains.
Which companies own or market Vaprisol?
Vaprisol was originally developed and marketed in the United States by Astellas-related entities. Cumberland Pharmaceuticals acquired U.S. rights to Vaprisol from Astellas in 2016. Cumberland disclosed an upfront payment of approximately $20 million in connection with the transaction, with additional contingent consideration tied to the acquired rights. [4]
| Period |
Commercial position |
| 2005 to 2016 |
Astellas-originated U.S. commercial ownership |
| 2016 onward |
U.S. rights acquired by Cumberland Pharmaceuticals |
| Current commercial model |
Specialty hospital product marketed through an institutional sales channel |
The transaction placed Vaprisol within Cumberland’s portfolio of branded hospital and specialty products. Cumberland’s public filings do not provide a consistent, separately reported Vaprisol revenue line. Product-specific revenue, gross margin, and EBITDA cannot therefore be established from public company reporting with precision. [4][5]
What is the financial trajectory for Vaprisol?
Vaprisol’s financial trajectory is likely characterized by a mature, low-volume hospital product profile rather than a growth-stage pharmaceutical profile.
The main financial factors are:
- No current compound-level exclusivity.
- Short treatment duration.
- Limited eligible patient population.
- Hospital-only administration.
- Possible substitution risk from a future generic injection.
- Potential price resilience if few suppliers serve the market.
- Low promotional requirements compared with primary-care drugs.
- Manufacturing and sterile-fill costs that can limit generic participation.
Cumberland’s acquisition economics suggest that the product was valued as a niche cash-flow asset rather than as a platform for substantial market expansion. The absence of separately reported product revenue prevents a reliable calculation of sales growth, market share, or return on invested capital. [4][5]
Revenue exposure
Vaprisol’s revenue exposure is concentrated in hospitals treating severe or clinically significant hyponatremia. Demand is affected by:
- Hospital admissions for heart failure and cirrhosis.
- Intensive-care utilization.
- Nephrology and critical-care prescribing.
- Institutional treatment protocols.
- Availability of oral vasopressin antagonists.
- Hospital pharmacy contracting.
- Generic supply availability.
Because the treatment course is short, revenue depends on patient throughput rather than recurring prescriptions. A single hospital contract can have commercial value, but the product has limited ability to generate durable patient-level recurring revenue.
How does Vaprisol compare with competing hyponatremia products?
Vaprisol competes with both pharmacologic and nonpharmacologic treatment approaches. The most relevant commercial comparison is with oral vasopressin antagonists, particularly tolvaptan, and with generic management strategies such as fluid restriction and hypertonic saline.
| Factor |
Vaprisol |
Tolvaptan |
Hypertonic saline and fluid restriction |
| Route |
Intravenous |
Oral |
Intravenous or oral management |
| Setting |
Hospital |
Hospital initiation; selected outpatient use |
Hospital |
| Treatment duration |
Short-term, up to four days |
Varies by indication |
Acute or protocol-driven |
| Active ingredient protection |
Expired |
Historically stronger, depending on indication and jurisdiction |
Generic or established treatment |
| Administration burden |
Continuous infusion |
Oral dosing |
Monitoring-intensive |
| Differentiation |
Ready-to-use IV formulation |
Oral convenience and broader clinical familiarity |
Lower drug acquisition cost |
| Generic substitution risk |
Meaningful |
Depends on indication and patent status |
High |
Vaprisol’s principal advantage is intravenous delivery for patients who cannot receive or do not respond adequately to oral treatment. Its principal disadvantage is the need for infusion and close monitoring.
What generic entry risks exist for Vaprisol?
Generic entry risk is structurally high because the product lacks an apparent current Orange Book patent barrier. The risk is moderated by the economics of the market.
High-risk factors
- Expired regulatory exclusivity.
- No identified active blocking patent listing.
- Established active ingredient.
- A relatively straightforward injectable dosage form.
- Potential for hospital formulary substitution.
- Limited brand differentiation beyond premixed packaging.
Factors that may delay generic entry
- Low market size.
- Sterile manufacturing requirements.
- Small commercial opportunity relative to ANDA development cost.
- Need to validate plastic-container compatibility.
- Risk of supply interruptions in a low-volume injectable market.
- Hospital purchasing processes that may favor an established supplier.
- Potentially limited reimbursement upside.
The most likely generic launch scenario is not a rapid multi-company price collapse. A more plausible scenario is entry by one or two injectable specialists, followed by selective hospital conversion and price pressure concentrated in tenders and group purchasing contracts.
What manufacturing and intellectual-property barriers affect Vaprisol?
The key barrier is manufacturing execution, not patent exclusivity.
A competing manufacturer would need to establish:
- Sterile compounding and aseptic filling.
- Validated container-closure systems.
- Stability through labeled shelf life.
- Compatibility with 5% dextrose.
- Control of visible and subvisible particulates.
- Consistent conivaptan assay and impurity profile.
- Packaging and shipping controls for a ready-to-use solution.
Plastic-container packaging can create technical risks involving adsorption, permeability, extractables, and leachables. Those risks can be material in an injectable product, but they generally support regulatory quality requirements rather than a durable patent moat.
Geographic protection is also limited. U.S. rights are commercially distinct from any rights in Europe, Japan, or other territories. The Cumberland transaction concerned U.S. rights, and no broad global exclusivity position should be inferred from that transaction. [4]
What litigation and settlement agreements affect Vaprisol?
No major publicly reported patent litigation or Paragraph IV settlement was identified as a current factor affecting Vaprisol’s U.S. market. The absence of litigation is commercially consistent with the lack of a visible active Orange Book patent estate.
No public settlement agreement appears to establish a delayed generic launch date or licensed generic arrangement for the product. Any supply, distribution, or hospital contracting arrangements would not necessarily be disclosed in public filings unless financially material.
How strong is the Vaprisol patent estate?
The patent estate is weak as a current exclusivity asset.
| Patent-estate factor |
Assessment |
| Composition-of-matter protection |
Expired or commercially ineffective |
| Formulation protection |
No active Orange Book barrier identified |
| Method-of-use protection |
No current blocking listing identified |
| Packaging protection |
Technical know-how may exist; no material listed patent barrier identified |
| Regulatory exclusivity |
Expired |
| Litigation leverage |
Limited |
| Generic vulnerability |
High, subject to market economics |
The product may retain commercial value through brand recognition, reliable supply, hospital relationships, and manufacturing know-how. Those assets are weaker than patent exclusivity but can preserve pricing in a low-competition injectable market.
What is the likely generic launch scenario?
Three scenarios define Vaprisol’s commercial outlook.
No generic entrant
Cumberland retains a niche market with relatively stable pricing. This outcome is possible if the market is too small to justify injectable development.
Single generic entrant
A single approved generic gains hospital contracts and causes moderate price erosion. The brand may retain share where supply reliability, product familiarity, or contract terms matter.
Multiple generic entrants
Several suppliers compete on price, producing significant erosion in net sales and margins. This scenario is more likely only if market demand and reimbursement support multiple manufacturers.
The highest-value commercial defense is supply reliability and institutional contracting. Patent litigation is unlikely to provide meaningful protection.
Key Takeaways
- Vaprisol in 5% Dextrose is an intravenous conivaptan hydrochloride product for short-term hospital treatment of euvolemic or hypervolemic hyponatremia.
- FDA approval dates to December 1, 2005, and regulatory exclusivity has expired.
- No active Orange Book-listed patent barrier was identified for the marketed injection presentation.
- Cumberland Pharmaceuticals acquired U.S. rights from Astellas in 2016 for approximately $20 million upfront, subject to contingent consideration.
- Public filings do not separately disclose Vaprisol revenue, preventing a reliable product-level financial forecast.
- The main competitive threat is an ANDA-based generic injectable, not a biosimilar.
- Sterile manufacturing, plastic-container compatibility, and market size may delay generic entry despite weak patent protection.
- The product’s commercial value depends on hospital demand, formulary access, supply reliability, and pricing discipline.
- The likely financial profile is mature and niche, with meaningful downside if one or more generic suppliers enter.
FAQs
Is Vaprisol still protected by patents?
No current blocking Orange Book patent was identified for the reviewed conivaptan hydrochloride injection entry. Any original active-ingredient protection has expired or no longer provides effective U.S. market exclusivity.
Is there a generic for Vaprisol in 5% Dextrose?
The principal commercial risk is a future or limited-market ANDA-approved generic conivaptan injection. The product’s small hospital market and sterile manufacturing requirements may limit the number of generic entrants.
Is Vaprisol a biosimilar product?
No. Vaprisol contains conivaptan hydrochloride, a small-molecule active ingredient. Generic approval would proceed through the ANDA pathway rather than the biosimilar pathway.
Why does the 5% dextrose container matter commercially?
The ready-to-use container reduces bedside preparation and may improve pharmacy workflow. Its value is operational rather than exclusivity-based. A generic manufacturer would need to demonstrate container compatibility, stability, sterility, and product quality.
What would most reduce Vaprisol revenue?
The largest likely revenue risks are generic entry, hospital formulary substitution, declining use of intravenous vasopressin antagonists, and pricing pressure from group purchasing organizations.
References
- U.S. Food and Drug Administration. (2005). Vaprisol (conivaptan hydrochloride) injection prescribing information.
- U.S. Food and Drug Administration. (2005). Vaprisol approval letter and regulatory review materials.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Cumberland Pharmaceuticals, Inc. (2016). Annual report and disclosures regarding acquisition of U.S. Vaprisol rights from Astellas Pharma US, Inc.
- Cumberland Pharmaceuticals, Inc. (2023). Form 10-K annual report.
